Genomic landscape of extraordinary responses in metastatic breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sun Min | - |
dc.contributor.author | Kim, Eunyoung | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Kim, Sora | - |
dc.contributor.author | Koo, Ja Seung | - |
dc.contributor.author | Kim, Seung Il | - |
dc.contributor.author | Park, Seho | - |
dc.contributor.author | Park, Hyung Seok | - |
dc.contributor.author | Park, Byoung Woo | - |
dc.contributor.author | Cho, Young Up | - |
dc.contributor.author | Kim, Ji Ye | - |
dc.contributor.author | Paik, Soonmyung | - |
dc.contributor.author | Kwon, Nak-Jung | - |
dc.contributor.author | Kim, Gun Min | - |
dc.contributor.author | Kim, Ji Hyoung | - |
dc.contributor.author | Kim, Min Hwan | - |
dc.contributor.author | Jeon, Min Kyung | - |
dc.contributor.author | Kim, Sangwoo | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.date.accessioned | 2021-12-01T09:40:07Z | - |
dc.date.available | 2021-12-01T09:40:07Z | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 2399-3642 | - |
dc.identifier.uri | https://yscholarhub.yonsei.ac.kr/handle/2021.sw.yonsei/5382 | - |
dc.description.abstract | Extreme responders to anticancer therapy are rare among advanced breast cancer patients. Researchers, however, have yet to investigate treatment responses therein on the whole exome level. We performed whole exome analysis to characterize the genomic landscape of extreme responders among metastatic breast cancer patients. Clinical samples were obtained from breast cancer patients who showed exceptional responses to anti-HER2 therapy or hormonal therapy and from those who did not. Matched breast tumor tissue (somatic DNA) and blood samples (germline DNA) were collected from a total of 30 responders and 15 non-responders. Whole exome sequencing using Illumina HiSeq2500 was performed for all 45 patients (90 samples). Somatic single nucleotide variants (SNVs), indels, and copy number variants (CNVs) were identified for the genomes of each patient. Group-specific somatic variants and mutational burden were statistically analyzed. Sequencing of cancer exomes for all patients revealed 1839 somatic SNVs (1661 missense, 120 nonsense, 43 splice-site, 15 start/stop-lost) and 368 insertions/deletions (273 frameshift, 95 in-frame), with a median of 0.7 mutations per megabase (range, 0.08 to 4.2 mutations per megabase). Responders harbored a significantly lower nonsynonymous mutational burden (median, 26 vs. 59, P = 0.02) and fewer CNVs (median 13.6 vs. 97.7, P = 0.05) than non-responders. Multivariate analyses of factors influencing progression-free survival showed that a high mutational burden and visceral metastases were significantly related with disease progression. Extreme responders to treatment for metastatic breast cancer are characterized by fewer nonsynonymous mutations and CNVs. | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Genomic landscape of extraordinary responses in metastatic breast cancer | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1038/s42003-021-01973-x | - |
dc.identifier.scopusid | 2-s2.0-85104158340 | - |
dc.identifier.wosid | 000639564600002 | - |
dc.identifier.bibliographicCitation | Communications Biology, v.4, no.1, pp 449 | - |
dc.citation.title | Communications Biology | - |
dc.citation.volume | 4 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 449 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in Scholar Hub are protected by copyright, with all rights reserved, unless otherwise indicated.
Yonsei University 50 Yonsei-ro Seodaemun-gu, Seoul, 03722, Republic of Korea1599-1885
© 2021 YONSEI UNIV. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.